CognitiveMedium Risk

Desmopressin

Also known as: DDAVP, dDAVP, Minirin, Stimate

Half-life:: 1.5-2.5 hours (intranasal)

Administration Routes

intranasaloralsubcutaneous injection

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Synthetic vasopressin analogue (V2R selective); crosses blood-brain barrier; enhances hippocampal LTP and memory consolidation; longer-acting than natural vasopressin

A synthetic vasopressin analogue with preferential V2R activity. Used medically for diabetes insipidus; studied off-label for memory enhancement and cognitive improvement.

Primary Research Areas

memory consolidation
learning enhancement
antidiuretic
hemostasis

Risk Profile

Medium Risk

Moderate risk profile in research contexts. Consult a healthcare professional before use.

Regulatory Status

Prescription OnlyFDA Approved

FDA-approved synthetic vasopressin analog. Brands: DDAVP (NDA 017922), Stimate, Nocdurna (NDA 201532, Jun 2018). Approved forms: injection, intranasal, oral, sublingual. Prescription only.

Effective: January 1, 1978View FDA source →

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Where to Find Desmopressin

No active associated providers listed yet.